In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- University of Toronto
- Enrollment
- 12
- Locations
- 2
- Primary Endpoint
- Whole-Body Protein Synthesis
Study Overview
Brief Summary
This study seeks to investigate the anabolic potential of a dileucine-enriched essential amino acid (EAA) formulation compared with a branched chain amino acid (BCAA) alternative and a collagen beverage on muscle protein anabolism and catabolism following a bout of resistance exercise training. To do this, investigators will employ a novel 'breath test' method developed in our laboratory as well as blood and urine sampling. The results of this study will allow us to better understand the anabolic potential of dileucine which could have implications for people engaging in regular resistance training (such as athletes) as well as people that need to preserve muscle mass (older people who are susceptible to anabolic resistance and sarcopenia, or muscle wasting).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Masking Description
Neither participants, investigators, or data analysts will be aware of the supplement assignment (labelled A-C) until data analysis for the primary outcome is complete.
Eligibility Criteria
- Ages
- 18 Years to 35 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Trained individuals currently performing structured exercise (e.g., running, weightlifting, team-sport activity) at least 2 days per week for the previous 3 months
Exclusion Criteria
- •Inability to perform physical activity as determined by the PAR-Q
- •Inability to adhere to protocol guidelines (e.g., alcohol, habitual diet)
- •Regular tobacco use
- •Illicit drug use (e.g., growth hormone, testosterone, etc.)
- •Diagnosed medical condition under the care of a physician (e.g. type 2 diabetes)
- •Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc.) at least three weeks before the trial
- •Individuals on any medications known to affect protein metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications)
- •Participants that are amenorrheic (females only)
- •On medications that may interfere with protein metabolism (e.g. anti-inflammatory drugs, hormone therapy)
- •Regular tobacco use (e.g. daily use of oral or inhaled tobacco)
- •Illicit drug use (e.g. growth hormone, testosterone, etc.)
- •Inability to comply with the study protocol as judged by the investigators
Outcomes
Primary Outcomes
Whole-Body Protein Synthesis
Time Frame: 6 hours
Investigators will measure the enrichment of \[13CO2\] in the breath by isotope ratio mass spectrometry (IRMS) in atom percent excess (APE). The measurement of carbon dioxide production (VCO2) and stable isotope tracer enrichment in the breath allows for the assessment of the rate at which amino acids are used for energy (i.e., oxidized), rather than for protein synthesis (i.e., retained in the body) by calculating the fraction of expired CO2 that contains 13C. Leucine retention (umol/kg) will then be calculated from the difference between the known amount of leucine provided (ingested) and leucine oxidation (as determined from 13CO2 breath enrichment).
Secondary Outcomes
- Murine Cell-Based Experiments (ex-vivo experiments) - Protein Synthesis(60 minutes)
- Murine Cell-Based Experiments (ex-vivo experiments) -hypertrophy(60 minutes)
- Urinary Measures (Muscle Protein Breakdown)(6 hours)
- Murine Cell-Based Experiments (ex-vivo experiments) - mTORC1 Signalling(60 minutes)
Investigators
Daniel Moore
Associate Professor
University of Toronto